癸酸氟哌啶醇与利培酮对社区精神分裂症患者维持疗效观察

A Study of Long-term Efficacy of Haloperidol Decanoate and Risperidone in the Treatment of Patients with Schizophrenia in Community

目的探讨癸酸氟哌啶醇与利培酮对社区精神分裂症患者维持疗效和安全性。方法选取80例出院的精神分裂症患者,依据其出院后1个月且病情稳定时服用的治疗药物,分为癸酸氟哌啶醇组(研究组)和利培酮组(对照组),进行为期12个月的随访观察。分别用阳性及阴性症状量表(PANSS)、个人和社会功能量表(PSP)、用药满意度问卷(MSQ)和不良反应量表(TESS)评估患者的症状、个人和社会功能、用药满意度以及药物不良反应。结果组间比较,PANSS、PSP和MSQ量表评分差异有统计学意义(P<0.05),研究组优于对照组。研究组复发率低于对照组(χ^2=4.31,P=0.038)。结论癸酸氟哌啶醇长效针剂对社区精神分裂症患者具有较好的维持治疗效果。

OBJECTIVE The research is to explore the long--term efficacy of Haloperidol decanoate and Risperidone in the treatment of patients with schizophrenia in community. METHOD A total of 80 inpatients were divided into two groups: the Haloperidol decano ate group( study group) and the Risperidones group( control group) according to the drugs they took a month after discharge from hospi tal and in stable condition. The two groups were evaluated at baseline and after one year of treatment respectively. The positive and negative symptom scale( PANSS) was used to evaluate the changes of psychotic symptoms. The Personal and Social performance scale (P SP) was used to evaluate the changes of quality of life and social function. The Medication Satisfaction Questionnaire( MSQ) was used to evaluate the changes of durg-using satisfaction. The side effects scale( TESS) was used for safety assessment. RESULT At the end of study, there were statistically significant difference in PANSS scores, PSP scores and MSQ scores between the two groups(P < 0.05) . The study group was better than the control group . The recurrence rate of the study group was lower than that of the control group(χ^2=4.31,P=0.038). CONCLUSION Haloperidol decanoate might better choice for long-term maintain treatment of patients with schizophrenia in community .